P
lasminogen activator inhibitor type-1 (PAI-1) is the primary inhibitor of tissue-type and urokinase-type plasminogen activators and therefore is considered to play an integral role in the control of the fibrinolytic system. 1 Furthermore, a growing body of evidence suggests that PAI-1 plays a crucial role in the development of atherosclerosis 2 and neointimal formation after balloon injury. 3 PAI-1 levels have been shown to be elevated in patients with hypertension, type 2 diabetes, insulin resistance, and hypertriglyceridemia, 4 which are known to accelerate atherosclerosis. Furthermore, it has been shown that PAI-1 expression is upregulated in atherosclerotic lesions. 2 An elevation of the plasma PAI-1 level is considered to facilitate fibrin deposition by reducing fibrinolytic activity. In addition, PAI-1 promotes fibrosis of the vessel wall by preventing the activation of matrix metalloproteinase by plasmin. 5 Angiotensin II (Ang II) has been implicated in the pathogenesis of atherosclerosis, hypertension, and neointimal formation after balloon injury. 6 Ang II causes hypertrophy of vascular smooth muscle cells (VSMCs), 7 extracellular matrix production, and the expression of various growth factors. 8 Although 2 Ang II receptor isoforms, designated type 1 receptor (AT 1 -R) 9 and type 2 receptor (AT 2 -R), 10 have been cloned, most of the cardiovascular effects are mediated by AT 1 -R. Ang II has been shown to activate various protein kinase pathways through AT 1 -R. It is well known that Ang II activates extracellular signal-regulated protein kinase (ERK), 11 which is a critical protein kinase for cell proliferation and gene expression, and that epidermal growth factor receptor (EGF-R) transactivation and Src kinase activation by Ang II are required for ERK activation. 12 Ang II also activates another class of mitogen-activated protein (MAP) kinases, such as p38 MAP kinase 13 and Jun N-terminal kinase (JNK). 14 Recently, the Rho family of small GTPase is reported to play an important role in Ang II signaling. 15 Rho A and Rho-kinase, one of the target proteins of Rho A, are implicated not only in cytoskeletal organization 16 but also in gene expression, including c-fos. 17 Although Ang II has been shown to increase PAI-1 production in VSMCs, 18 the molecular mechanism responsi-ble for the induction is not clarified. The aim of the present investigation is to clarify the signaling pathways for PAI-1 induction by Ang II. We demonstrated in the present study that Ang II-induced PAI-1 expression was dependent on an AT 1 -R-mediated increase in the intracellular calcium level, activation of tyrosine kinase, and EGF-R transactivation. Furthermore, the activation of ERK and Rho-kinase pathways plays a pivotal role in the upregulation of PAI-1 gene expression by Ang II. These findings are important pathophysiological implications for the pathogenesis of atherosclerosis, neointimal formation, and hypertension.
Methods

Reagents
Ang II was purchased from the Peptide Institute. PD98059 was obtained from Research Biochemicals International. BSA, genistein, and tyrphostin AG1478 were purchased from Sigma Chemical Co. BAPTA-AM was purchased from Dojindo. Benidipine was obtained from Kyowa Hakko. DMEM and FBS were purchased from GIBCO-BRL. [␣-
32 P]dCTP was purchased from Du-Pont NEN. CV11974 was obtained from Takeda Chemical Industries, and PD123319 was obtained from Warner-Lambert, Park Davis Co. Y27632 was provided by Yoshitomi Pharmaceutical Co. Rabbit anti-rat PAI-1 IgG was acquired from American Diagnostica, and alkaline phosphataseconjugated goat anti-rabbit IgG was obtained from New England Biolabs. A specific antibody against phosphorylated myosin binding subunit (MBS) of myosin phosphatase was a gift from Dr Kaibuchi (Nara Institute of Science and Technology, Nara, Japan). Other chemical reagents were purchased from WAKO Pure Chemical, unless mentioned specifically.
Cell Culture
VSMCs were isolated from the thoracic aortas of Sprague-Dawley rats and maintained as described previously. 19 Passages between 6 and 12 were used for the experiments.
Northern Blot Analysis
Total RNA was prepared by an acid guanidinium-phenol-chloroform extraction method, and Northern blot analysis was performed as described previously. 20 The radioactivity of hybridized bands of PAI-1 mRNA and of 18S rRNA was quantified by a MacBAS Bioimage Analyzer (FUJIFILM). An EcoRI/PstI (0.6 kb) fragment of a bovine PAI-1 cDNA was used as a probe.
Western Blot Analysis
Equivalent amounts of protein from conditioned medium were diluted 1:1 with sample buffer (0.25 mol/L Tris-HCl, pH 6.8, 40% glycerol, 4% SDS, 20% 2-mercaptoethanol, and 0.01% bromphenol blue) and loaded on a 10% SDS-polyacrylamide gel. The expression of PAI-1 in the conditioned media was assayed by Western blot as previously described. 21 VSMCs were lysed in RIPA buffer (50 mmol/L NaCl, 30 mmol/L sodium pyrophosphate, 50 mmol/L NaF, 5 mmol/L EDTA, 10 mmol/L Tris, pH 7.4, 1% Triton X-100, 1 mmol/L phenylmethylsulfonyl fluoride, 0.2 U/mL aprotinin, 10 mmol/L pepstatin A, and 25 mmol/L leupeptin). The lysates were subjected to 12% SDS-PAGE and transferred to polyvinylidene difluoride membranes (Millipore). The membrane was probed by use of antibodies against phospho-ERK1/2 and ERK1/2 (New England Biolabs) and an enhanced chemoluminescence detection system (Amersham). Phosphorylation of ERK is reported to be correlated with activation. 11 Therefore, we used the phosphorylation of ERK as a measure of its activation.
To evaluate Rho-kinase activity, the extent of phosphorylation of MBS (a substrate of Rho-kinase) 22 was measured by Western blot analysis with use of a specific antibody against phosphorylated MBS as described above.
Measurement of PAI-1 Gene Promoter Activity
VSMCs were prepared in a 6-cm tissue culture dish. After 48 hours, 5 g of PAI-1 promoter 23 (Ϫ760 bp)-luciferase fusion DNA construct and 2 g of LacZ gene driven by the SV40 promoterenhancer sequence were introduced to VSMCs by the DEAE dextran method as previously described. 24 These cells were cultured in DMEM supplemented with 10% FBS for 24 hours and stimulated with Ang II (10 Ϫ6 mol/L) in DMEM containing 0.1% BSA for 24 hours. The luciferase activity was measured and normalized by ␤-galactosidase activity as described previously. 19 
Infection of Recombinant Adenoviruses
Adenoviruses expressing a dominant-negative mutant of Rho-kinase (AdD/N RhoK) or bacterial ␤-galactosidase (AdLacZ) were gifts from Dr Kaibuchi (Nara Institute of Science and Technology, Nara, Japan). AdD/N RhoK expresses the Rho-binding domain of Rhokinase. The Rho-binding domain binds to Rho and inhibits Rhodependent Rho-kinase activity. 25 VSMCs were incubated with PBS containing adenovirus vector for 2 hours at room temperature under gentle agitation. Then these cells were washed and incubated for an additional 2 days under serum-free conditions and used for the experiments. Multiplicity of infection indicates the amount of adenovirus per cell added to culture dish.
Statistical Analysis
Statistical analyses of the relative PAI-1 mRNA expression were performed by using 1-way ANOVA and the Fisher test if appropriate. Degradation of PAI-1 mRNA was analyzed by 2-way ANOVA. Data are shown as meanϮSEM. A value of PϽ0.05 was considered to be significant.
Results
Enhancement of PAI-1 mRNA and Protein Expression by Ang II
We examined the time course of Ang II-induced PAI-1 mRNA expression. A transient increase in PAI-1 mRNA expression by Ang II was observed ( Figure 1A) . The expression of PAI-1 mRNA by Ang II was increased dosedependently ( Figure 1B ). CV11974, a specific AT 1 -R antagonist, completely abolished the PAI-1 mRNA induction by Ang II. However, PD123319, a specific AT 2 -R antagonist, showed no effect ( Figure 1B) . These results suggest that Ang II increases PAI-1 mRNA expression through AT 1 -R. Western blot analysis showed that PAI-1 protein levels in the supernatant of VSMCs were increased time-dependently ( Figure 1C ) and dose-dependently ( Figure 1D ). The increase in PAI-1 protein by Ang II was inhibited by CV11974 but not by PD123319 ( Figure 1D ).
Transcriptional and Posttranscriptional Regulation of PAI-1 Gene Expression by Ang II
As shown in Figure 2A , the PAI-1 promoter activity was significantly increased by Ang II (10 Ϫ6 mol/L, 1.4-fold of control), and Ang II significantly increased the stability of PAI-1 mRNA compared with that of unstimulated cells ( Figure 2B ). These data suggest that Ang II upregulates PAI-1 mRNA expression by transcriptional and posttranscriptional mechanisms. Although treatment with cycloheximide, an inhibitor of translation, alone resulted in an increase in basal PAI-1 mRNA expression as reported previously in endothelial cells, 26 Ang II increased PAI-1 mRNA expression in the presence of cycloheximide (online Figure I , which can be accessed at http://atvb.ahajournals.org). These data suggest that this process does not require de novo protein synthesis.
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Next, we examined the Ang II signaling responsible for PAI-1 gene expression. Although pretreatment with genistein, a tyrosine kinase inhibitor, or PD98059, an ERK kinase (MEK) inhibitor, slightly decreased basal PAI-1 mRNA expression, these compounds almost completely suppressed Ang II-induced PAI-1 mRNA upregulation ( Figure 3 ). In contrast, SB203580, a p38 MAP kinase inhibitor, did not affect basal and Ang II-stimulated PAI-1 mRNA upregulation (Figure 3 ). These data suggest that tyrosine kinase and MEK/ERK pathways rather than the p38 MAP kinase pathway are crucial in Ang II-induced PAI-1 gene upregulation. Protein kinase C (PKC) activation has been shown to enhance PAI-1 production in several cell lines. 27 We examined the effect of 2 different PKC inhibitors on Ang II-induced PAI-1 mRNA expression. Although pretreatment with GF109203X or calphostin C slightly affected basal expression of PAI-1 mRNA, Ang II-induced upregulation of PAI-1 mRNA was not inhibited by these inhibitors (online Figure II , which can be accessed online at http://atvb.ahajournals.org). These data suggest that the PKC pathway does not play a dominant role in Ang II-induced PAI-1 mRNA upregulation.
Roles of Intracellular Calcium and EGF-R Transactivation for Ang II-Induced PAI-1 Upregulation
BAPTA-AM, an intracellular calcium chelator, completely inhibited Ang II-induced PAI-1 mRNA expression, but benidipine, a calcium channel blocker, did not ( Figure 4A ). These results suggest that Ang II activates PAI-1 gene expression through an intracellular calcium-dependent pathway. Next, we examined the effect of tyrphostin AG1478, a specific EGF-R inhibitor, on Ang II-induced PAI-1 upregulation. Although AG1478 alone slightly decreased basal PAI-1 mRNA levels, AG1478 completely abrogated Ang II-induced PAI-1 mRNA upregulation ( Figure 4B ), suggesting that EGF-R transactivation is essential for this process.
Critical Role of Rho-Kinase Pathway for Ang II-Induced PAI-1 Upregulation
Y27632, a Rho-kinase inhibitor, almost completely suppressed Ang II-induced PAI-1 upregulation (10 Ϫ5 mol/L, Figure 5A ). To exclude the possible nonspecific effect of Y27632, we took an advantage of AdD/N RhoK, which specifically inhibits the Rho-kinase pathway. 25 Although Ang II-induced PAI-1 gene expression was not inhibited by infection of AdLacZ, it was almost completely abrogated by infection of AdD/N RhoK in a multiplicity-of-infectiondependent manner ( Figure 5B ). These findings suggest that the Rho-kinase pathway is important for Ang II-induced PAI-1 upregulation in VSMCs.
It has previously been reported that Rho A activation decreases endothelial NO synthase mRNA stability. 28 We examined whether activation of Rho-kinase would affect the mRNA stability of PAI-1. As shown in Figure 2B , blockade of Rho-kinase by Y27632 partially reversed the Ang IIinduced stabilization of PAI-1 mRNA. This result suggests that Ang II-induced Rho-kinase activation may be partially responsible for the stabilization process of PAI-1 mRNA.
The Relationship of MEK/ERK and Rho-Kinase
To clarify the relationship between MEK/ERK and Rhokinase, we examined whether the Rho-kinase pathway was involved in Ang II-induced ERK activation. Ang II-induced ERK1/2 phosphorylation was inhibited by PD98059 but not by Y27632 ( Figure 6A) or AdD/N RhoK ( Figure 6B ). The phosphorylation of MBS, which reflects the activation of Rho-kinase, 22 was inhibited by Y27632; however, PD98059 showed no effect ( Figure 6C ). These results suggest that MEK/ERK and Rho-kinase may be independent of each other in the signaling of Ang II.
Discussion
We demonstrated that Ang II stimulated PAI-1 gene expression through AT 1 -R in cultured VSMCs. Ang II increased PAI-1 promoter activity and prolonged PAI-1 mRNA halflife. Activation of Rho-kinase and MEK/ERK pathways was crucial in Ang II-induced PAI-1 mRNA upregulation.
Although Ang II enhanced PAI-1 promoter activity only moderately, Ang II consistently increased the PAI-1 mRNA level by severalfold ( Figure 1A) . The discrepancy between the result of luciferase assay and that of Northern blot analysis could be explained by the finding that Ang II 
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significantly prolonged the PAI-1 mRNA half-life ( Figure  2B ). In other words, Ang II increases PAI-1 mRNA expression at transcriptional and posttranscriptional levels. PAI-1 mRNA was superinduced by cycloheximide (online Figure I) . The 3Ј untranslated region of PAI-1 mRNA contains AU-rich elements, 29 which is related to the mRNA instability. Therefore, Ang II may affect the PAI-1 mRNA stability though these AU-rich sequences. Activation of calcium-sensitive tyrosine kinase (Pyk2) and transactivation of EGF-R is indispensable for Ang II-induced ERK activation. 12 In trying to delineate the signal transduction pathway regulating PAI-1 gene expression by Ang II, we found that ERK activation played a crucial role. As expected from previous reports, inhibition of the upstream signaling of ERK by BAPTA-AM, genistein, or AG1478 abrogated Ang II-induced PAI-1 mRNA expression.
Rho A and Rho-kinase, one of the target proteins of Rho A, participate not only in cytoskeletal organization 16 but also in gene expression. 17 Ang II-induced atrial natriuretic peptide (ANP) gene expression was completely inhibited by Botulinum C3 exoenzyme, 15 which specifically inactivates Rho A. 30 It has also been reported that endothelin-induced ANP gene expression is inhibited by Y27632 as well as the C3 exoenzyme in cardiac myocytes. 31 These data suggest that the Rho A/Rho-kinase pathway mediates the Ang II-induced and endothelin-induced ANP gene expression. Our data suggest that the Rho-kinase pathway also plays an important role in PAI-1 gene expression by Ang II. The precise molecular mechanism of Rho-kinase-dependent PAI-1 gene upregulation requires further investigation. One possible explanation is the interaction between the Rho A/Rho-kinase and MEK/ ERK pathways. A previous report demonstrated that Rho A was involved in the lysophosphatidic acid-induced ERK activation in NIH 3T3 cells. 32 However, Rho A was not involved in the Ang II-induced ERK activation in cardiac myocytes. 33 Although we could not exclude the possibility that Rho A is upstream of ERK in Ang II signaling, we clearly demonstrated that inhibition of Rho-kinase did not affect Ang II-induced ERK activation ( Figure 6A and 6B) . Furthermore, Ang II-induced Rho-kinase activation was not inhibited by the blockade of MEK ( Figure 6C ). These results suggest that MEK/ERK and Rho-kinase may be activated separately by Ang II.
Previous reports have suggested that activation of Rho A enhances activator protein-1 34 and Ets 35 transcriptional activity. Because there are some consensus elements, such as activator protein-1 and Ets, in the promoter of PAI-1 gene, 23 Ang II activates Rho A 15 and may positively regulate PAI-1 gene expression through these elements. A recent report suggests that Rho-kinase directly regulates transcriptional factors, such as serum response factor, in response to activated Rho A. 17 Therefore, it is possible that these transcriptional factors are responsible for Ang II-induced PAI-1 upregulation via Rho-kinase activation. Further study is necessary to determine the critical response element of PAI-1 gene promoter and the trans-acting factor.
An increase in PAI-1 level has been considered to be a risk factor for atherothrombotic events. 1 Inhibition of PAI-1 action or suppression of PAI-1 production may be novel strategies for the prevention of cardiovascular disease. A growing body of reports suggests the beneficial effects of ACE inhibitors or AT 1 -R antagonists in the treatment of cardiovascular diseases. Suppression of Ang II-induced PAI-1 upregulation may contribute to the beneficial effects of ACE inhibitors or AT 1 -R antagonists. The pathophysiological importance of our observation was that inhibition of Rhokinase blocked Ang II-mediated PAI-1 gene expression. Thus, the Rho-kinase pathway may be a novel target in the inhibition of Ang II signaling, and its inhibition may be useful in the treatment of not only hypertension but also atherosclerosis and neointimal formation. 22 
